The Role of FBXW7 in Gynecologic Malignancies
Cells · 17.05.2023 · 12 (10) · 1415
DOI: 10.3390/cells12101415 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 17.05.2023. Verfasst von Riccardo Di Fiore und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta. Hauptthemen laut MEDLINE: F-Box Proteins, Genital Neoplasms, Female. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Co-operation in Science and Technology (COST).
Abstract (Originalsprache)
The F-Box and WD Repeat Domain Containing 7 (FBXW7) protein has been shown to regulate cellular growth and act as a tumor suppressor. This protein, also known as FBW7, hCDC4, SEL10 or hAGO, is encoded by the gene FBXW7. It is a crucial component of the Skp1-Cullin1-F-box (SCF) complex, which is a ubiquitin ligase. This complex aids in the degradation of many oncoproteins, such as cyclin E, c-JUN, c-MYC, NOTCH, and MCL1, via the ubiquitin-proteasome system (UPS). The FBXW7 gene is commonly mutated or deleted in numerous types of cancer, including gynecologic cancers (GCs). Such FBXW7 mutations are linked to a poor prognosis due to increased treatment resistance. Hence, detection of the FBXW7 mutation may possibly be an appropriate diagnostic and prognostic biomarker that plays a central role in determining suitable individualized management. Recent studies also suggest that, under specific circumstances, FBXW7 may act as an oncogene. There is mounting evidence indicating that the aberrant expression of FBXW7 is involved in the development of GCs. The aim of this review is to give an update on the role of FBXW7 as a potential biomarker and also as a therapeutic target for novel treatments, particularly in the management of GCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta.
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
- BioDNA Laboratories, Malta Life Sciences Park, SGN 3000 San Gwann, Malta.
- School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK.
- Whipps Cross Hospital, Barts Health NHS Trust, Leytonstone, London E11 1NR, UK.
- Department of Breast Surgery, "Dr. Shterev" Hospital, 1330 Sofia, Bulgaria.
ORCID-Profile: Riccardo Di Fiore, Yashwanth Subbannayya, Mariela Vasileva-Slaveva, Angel Yordanov, Francesca Pentimalli, Jean Calleja-Agius
Förderung
- European Co-operation in Science and Technology (COST)
Zitieren
APA
Di Fiore, R., Suleiman, S., Drago-Ferrante, R., Subbannayya, Y., Suleiman, S., Vasileva-Slaveva, M., Yordanov, A., Pentimalli, F., Giordano, A., & Calleja-Agius, J. (2023). The Role of FBXW7 in Gynecologic Malignancies. Cells, 12(10), 1415. https://doi.org/10.3390/cells12101415
Vancouver
Di Fiore R, Suleiman S, Drago-Ferrante R, Subbannayya Y, Suleiman S, Vasileva-Slaveva M, et al. The Role of FBXW7 in Gynecologic Malignancies. Cells. 2023;12(10):1415. doi:10.3390/cells12101415
BibTeX
@article{DiFiore2023,
author = {Di Fiore, Riccardo and Suleiman, Sherif and Drago-Ferrante, Rosa and Subbannayya, Yashwanth and Suleiman, Sarah and Vasileva-Slaveva, Mariela and Yordanov, Angel and Pentimalli, Francesca and Giordano, Antonio and Calleja-Agius, Jean},
title = {The Role of FBXW7 in Gynecologic Malignancies},
journal = {Cells},
year = {2023},
volume = {12},
number = {10},
pages = {1415},
doi = {10.3390/cells12101415}
}
EUVIMED